On May 15, 2025, Travere Therapeutics announced that the FDA accepted its application for traditional approval of FILSPARI® for a rare kidney condition (FSGS), with a target decision date set for January 13, 2026. This is significant because if approved, it would be the first FDA-approved treatment for FSGS, affecting over 40,000 patients in the U.S.